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Abstract
Background: Type 2 diabetes mellitus (T2DM) and prediabetes have increased in prevalence among overweight and obese
children, with significant implications for long-term health. There is little published evidence on the best approaches to care of
prediabetes among overweight youth or the current practices used across pediatric weight management programs.
Methods: This article reviews the literature and summarizes current practices for screening, diagnosis, and treatment of predia-
betes at childhood obesity treatment centers. Findings regarding current practice were based on responses to an online survey from
28 pediatric weight management programs at 25 children’s hospitals in 2012. Based on the literature reviewed, and empiric data,
consensus support statements on prediabetes care and T2DM prevention were developed among representatives of these 25 chil-
dren’s hospitals’ obesity clinics.
Results: The evidence reviewed demonstrates that current T2DM and prediabetes diagnostic parameters are derived from adult-
based studies with little understanding of clinical outcomes among youth. Very limited evidence exists on preventing progression of
prediabetes. Some evidence suggests that a significant proportion of obese youth with prediabetes will revert to normoglycemia
without pharmacological management. Evidence supports lifestyle modification for children with prediabetes, but further study of
specific lifestyle changes and pharmacological treatments is needed.
Conclusion: Evidence to guide management of prediabetes in children is limited. Current practice patterns of pediatric weight
management programs show areas of variability in practice, reflecting the limited evidence base. More research is needed to guide
clinical care for overweight youth with prediabetes.
Introduction
T
he increased prevalence of obesity, particularly se-
vere obesity, in all pediatric age groups, has been
accompanied by an increase in type 2 diabetes mel-
litus (T2DM), prediabetes, and insulin resistance (IR).1–4
Along with other comorbidities of obesity, including hy-
pertension, dyslipidemia, fatty liver disease, musculoskeletal
disorders, and cardiovascular disease, T2DM and its com-
plications represent a significant cause of long-term dis-
ability within the US population and a challenge to the
resources of the US healthcare system.5–7 Still, little evi-
dence exists in pediatric populations for effective prevention
and treatment of T2DM.2,6,8 Currently, it is estimated that
one third of US youth are overweight or obese, and up to
15% of adolescents may have prediabetes and/or diabetes.1
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Adolescents and young adults with T2DM are expected to
lose 15 years from their life expectancy and may experience
severe, chronic complications by their forties.7,9–11 Most
diagnostic tools and therapeutic interventions currently in
use for pediatric T2DM are based on information extrapo-
lated from adult literature. However, the pathophysiology
and response to treatment varies between children and
adults. The TODAY study, the first long-term study of
children with T2DM, and others have reported faster pro-
gression of T2DM and beta-cell failure in children, com-
pared to adults, and poor treatment results.12–15
Data collected from 2001 through 2005 as part of the
SEARCH study,16 a large, multi-center study of physician-
diagnosed diabetes among youth 0–19 years of age, provide
estimates of prevalence and incidence rates of T2DM by age
and ethnicity. The prevalence of T2DM in 2001 was lowest
amongnon-Hispanicwhite youths 10–19years of age at 0.18 in
1000, with an incidence of 3.7 per 100,000 person-years during
the 4-year study.17 Prevalence and incidence rates were higher
among African American (1.06 in 1000; 19.0 per 100,000
person-years), Hispanic (0.46, 11.6), and Asian/Pacific Island
youth (0.52, 12.1) than non-Hispanic white youth, with the
highest rates among Navajo youth (1.45; 27.7).18–21
The impetus to complete this survey of current practice and
review of current evidence stems from the high prevalence of
childhood and adolescent obesity, increasing diagnosis of
prediabetes and T2DM, and interest in earlier identification
and prevention.22,23 The primary aims of the article are to
identify practices supported by evidence and report consensus
of current practice among childhood obesity specialists for
two areas: (1) screening of obese children and adolescents for
prediabetes and T2DM and (2) prevention of progression
from prediabetes to T2DM. This article describes the prac-
tices of medical weight management clinics, but is also rel-
evant to primary care providers who either manage obese
children collaboratively with weight management programs
or those who must address these issues without access to
outpatient tertiary care weight management.2,24 The article
also highlights subsets of the pediatric population identified
as having unique needs or differences with respect to the
diagnosis and management of prediabetes, such as specific
age groups,25 racial/ethnic groups,2,9,10 and patients with co-
occurring conditions or treatments (e.g., antipsychotics).
Methods
The clinical practices that are included in this literature
review and survey were identified by consensus of the
Medical Management Committee of the FOCUS on a
Fitter Future (FFF) Group, sponsored by the Children’s
Hospital Association (CHA). Over 5 years (2008–2013),
the FFF group of over 100 representatives from 28 weight
management programs at children’s hospitals across the
United States met in person quarterly and by telephone
weekly to monthly.26 Each institution self-selected to
participate in FFF by an application process available to
250 member institutions of the CHA. The FFF group was
unique during this time period as a multidisciplinary lon-
gitudinal working group of clinical experts and researchers
focusing on the treatment of childhood obesity, particu-
larly severe obesity.
Components of practice were included in this survey and
review because the committee judged each to raise relevant
clinical questions, have uncertain evidence support, and/or
be potential sources of variation in care. Current practices
are reported from a survey of 28 pediatric weight man-
agement programs at 25 children’s hospitals with wide
geographic distribution across the United States. The sur-
vey was completed by at least one provider from each of the
sites participating in the FFF group in 2012. Three hospitals
had more than one obesity clinic or program employing
different clinical approaches and therefore completed a
survey for each program to capture practice variation.
The interprofessional Medical Management Committee
from FFF (the Committee) rated the quality of available
evidence and determined the strength of support for each
practice using a framework described by the American
Academy of Pediatrics (AAP) Steering Committee on
Quality Improvement and Management.27 The quality of
evidence supporting each practice was assigned as: A.Well-
designed randomized, controlled trials (RCTs) or diag-
nostic studies on relevant populations, B. RCTs with minor
limitations or overwhelmingly consistent observational
studies, C. Observational studies, or D. Expert opinion. The
quality of evidence and the balance of benefits and harms
for each practice were weighed to arrive at a consensus
statement within the following categories: strong support
for the practice; support for the practice; an option to
consider the practice; no position; or a do not support
statement for the practice. Conclusions of the Committee
were presented at a meeting of the entire FFF group, from
which feedback was incorporated. The revised statements
were approved by the entire FFF group as consensus
statements. Members of the following disciplines were
involved in the review process: pediatricians, pediatric
endocrinologists, dietitians, psychologists, social workers,
exercise physiologists, and physical therapists. The group
identified opportunities for further research based on evi-
dence reviewed and variations within current practice.
Results
Identification of Risk
The American Diabetes Association (ADA) Expert
Committee on the Diagnosis and Classification of Diabetes
Mellitus first recognized prediabetes in 1997.28 Prediabetes
can be defined by abnormal glucose regulation, including
impaired fasting glucose and/or impaired glucose tolerance
(IGT) and/or glycosylated hemoglobin (A1c). Data from
adult and adolescent studies have shown that prediabetes,
particularly in those with an elevated BMI, significantly
increases the risk of developing diabetes, but is reversible.29
In one study, up to 50% of severely obese adolescents
with prediabetes returned to normal glucose tolerance over
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20 months, whereas 24% showed progression from predia-
betes to diabetes,29 and those with the highest BMI had the
highest risk of disease progression. Another study showed
that 75% of obese white teens with IGT returned to normal
glucose metabolism, whereas 2% progressed to diabetes.30
Based largely on data from the Diabetes Prevention Program
(DPP) Research Group study showing successful delay or
prevention of onset of T2DM in adults,31 there is mounting
interest in early detection of prediabetes in childhood.
Clinical screening. Medical providers who routinely carry
out laboratory screening of obese children, as recommended
by professional societies, are likely to identify some children
with blood glucose or A1c measurements in the prediabetes
range. Table 1 summarizes recommendations for T2DM
screening adapted from the 2007 Expert Committee Re-
commendations Regarding the Prevention, Assessment, and
Treatment ofChild andAdolescentOverweight andObesity.32
Special at-risk populations. In addition to obesity, mul-
tiple factors add to diabetes risk and warrant consider-
ation.33,34 Genetic and environmental risk factors include
female gender, sedentary behavior, and family history of
T2DM.35 Female adolescents are 1.7 times more likely
than boys to develop T2DM.36,37 At least 74% of children
with T2DM have a first- or second-degree relative with the
disorder.38 Risk is increased if a parent develops T2DM
before age 30.39 Prenatal nutrition and intrauterine envi-
ronment affect risk; low and high birth weight and ma-
ternal gestational diabetes or T2DM are the greatest risk
factors.39–44 Ethnic minorities are at higher risk, including
African Americans, Hispanics, and Native Americans.2,10
Finally, fat distribution plays a role; children who have
central obesity with higher visceral or abdominal fat stores
are at higher risk for IR and progression to diabetes.45,46
Patients prescribed second-generation antipsychotics
(SGAPs) are another group at increased risk for weight gain
and secondary diabetes. Among adults with schizophrenia
and affective disorders taking SGAPs, the prevalence of di-
abetes is estimated at 1.5–2.0 times that of the general pop-
ulation.47 The pediatric literature is limited; however, one
retrospective chart review estimated a 4-fold increased inci-
dence of diabetes among SGAP-exposed pediatric patients,
compared to nonpsychotropic medication users.48 An obser-
vational study of metabolic effects of SGAP therapy in chil-
dren found an average weight gain of 8.5 kg in 11 weeks.49
Clinical practice by children’s hospital-based weight
management clinics in screening for prediabetes and type 2
diabetes mellitus. All respondents, representing 28 pro-
grams at 25 children’s hospitals, indicated that they screen
patients for prediabetes and T2DM. Twenty five clinics
reported the criteria used to target screening. The majority
(n = 18 of 25; 72%) used BMI as a criterion; however,
cutpoints varied among programs (four screen for BMI
‡ 95th percentile, three for ‡ 85th percentile, one for > 40
kg/m2, and one for ‡ 99th percentile or ‡ 95th percentile
with comorbidities). Seven sites screen all referred pa-
tients. Additional factors used to target screening included
acanthosis nigricans (n= 4), family history of T2DM
(n = 2), age (n= 3), and clinical signs of diabetes (n= 1).
Consensus statement of Focus on a Fitter Future on
clinical screening. Overweight children with cardiome-
tabolic comorbidity and obese children should be
screened periodically for prediabetes and T2DM after
age 10 years or after onset of puberty (Evidence D).
Early identification of prediabetic or diabetic state may
prevent progression of disease or facilitate disease
management. Additional study of the predictive value of
abnormal blood glucose measures for the development
of T2DM in children is needed.
Table 1. Type 2 Diabetes Screening in
Asymptomatic Pediatric Patientsa,32
BMI criteria for screening
1. All children or adolescents who are severely obese (BMI >99th
percentile)
2. Children or adolescents at the earlier age of 10 or onset of
puberty with
a) Obesity (BMI ‡ 95th percentile)
b) Overweight (BMI 85th–< 95th percentile) with one or more
additional risk factors
Risk factors
 Family history of T2DM in first- or second-degree relative
 High-risk race/ethnicity (African American, Latino, Native
American, Asian American, or Pacific Islander)
 Signs of insulin resistance or conditions associated with
insulin resistance (hypertension [systolic or diastolic blood
pressure > 95th percentile for age and sex], dyslipidemia,
polycystic ovary syndrome, acanthosis nigricans, or small for
gestational age at birth)
 Maternal history of diabetes or gestational diabetes during
the child’s gestation, low or high birth weight
 Patients prescribed SGAPs
Age at initial testing
 10 years or at onset of puberty if puberty occurs at a younger age.
 Under age 10, or prepubertal if child has BMI > 99th percentile
or has one or more additional risk factors.
Retesting
 Biannually if normal, more frequently for abnormal values,
rapid increases in weight, development of other comorbidities
(hypertension or dyslipidemia), and/or onset of puberty.
aAdapted from 2007 Expert Committee Recommendations
Regarding the Prevention, Assessment, and Treatment of Child
and Adolescent Overweight and Obesity.32
SGAPs, second-generation antipsychotics.
294 HAEMER ET AL.
Laboratory Screening and Diagnostic Tests
Tests recommended by the ADA for screening and di-
agnosing prediabetes and diabetes include fasting plasma
glucose (FPG), A1c, and a 2-hour oral glucose tolerance
test (OGTT).38,50 Test selection for individual patients may
vary based on the clinical findings, risk factors, and re-
sources available. Relative advantages of fasting glucose
and A1c as screening tests are listed in Table 2,50 and
diagnostic cutoffs are listed in Table 3.38,50 An analysis of
laboratory data from 1156 overweight and obese adoles-
cents from National Health and Nutrition Examination
Survey 1999–2006 found that an A1c cutoff of 6.5% was
75% sensitive for identifying diabetes, compared to a
single FPG, though this study was limited by a very low
number of undiagnosed diabetics (n = 4) and the possibility
of erroneous reports of fasting.51 The same study found
that, for adolescents compared to adults, A1c was a sig-
nificantly worse predictor of prediabetes defined by FPG
(area under the receiver operating curve, 0.61 vs. 0.74;
p< 0.01). A recent position statement from the Pediatric
Endocrine Society notes that the diabetes diagnostic criteria
are based on long-term health outcomes assessed in adults,
but have not been validated in pediatric populations.52
Indices of insulin resistance. Accurate testing of IR is
labor intensive, invasive, and expensive (i.e., the hyper-
insulinemic-euglycemic and hyperglycemic clamp tech-
niques).53 Therefore, several indices have been developed
and studied, such as the homeostatic model assessment of
insulin resistance (HOMA-IR), the quantitative insulin
sensitivity check index, the continuous infusion of glucose
with model assessment, and the Matsuda index.54–60 The
most widely used and studied is HOMA-IR. No known
international standards for abnormal levels currently exist
for these indices in children, the assay itself is not stan-
dardized, and studies have shown that insulin indices do
not substantially change predictive value for diabetes
beyond other more-routine measures.29,61 The findings of
these studies highlight the concern that insulin levels may
be a poor predictor of diabetes risk because, whereas
IR may be accompanied by high insulin levels initially,
insulin secretion may decrease later in the progression
toward diabetes as a result of glucotoxicity and beta-cell
failure.
Clinical practice findings for tests used to screen for
prediabetes. All 28 respondents reported screening for
prediabetes, using a variety of test combinations. The most
widely used tests were A1c (n = 23) and FPG (n = 22), with
OGTT used less often (n = 10). Three clinics used A1c
alone, five used fasting glucose alone, 14 used fasting
glucose plus A1c, and six used all three tests for initial
screening. Most respondents repeated normal laboratory
tests either in 12 months (n= 9) or between 6 and 12
months (n= 9). Some respondents repeated normal labs
sooner, at 3–6 months (n = 5) and later at 12–24 months
(n = 2). For abnormal laboratory tests, most repeated tests
at either 3–6 (n = 9) or 6–12 months (n = 8). A few (n = 3)
repeated screening on an as-needed basis.
Clinical practice findings for screening for insulin resis-
tance. All respondents reported screening for IR by as-
sessing for acanthosis nigricans on physical examination.
Twenty-two of 25 (88%) respondents screened for IR using
fasting insulin or a ratio of fasting glucose to insulin. There
was marked variability in the criteria used to identify
children to be screened: Thirteen clinics (52%) screened
all children who were referred for weight management. Of
the remaining 12 clinics, four used BMI percentile criteria
only (two > 95th and two > 99th), six used the presence
of acanthosis nigricans and a BMI cutoff (one > 85th
percentile with risk factors and five > 95th percentile), and
Table 3. Summary of Criteria
for Diagnosing Prediabetes and Diabetes38,50
Prediabetes Diabetesd
Fasting plasma glucosea 100–125 mg/dL ‡126 mg/dL
2-hour plasma glucose (OGTT)b 140–199 mg/dL ‡200 mg/dL
Random plasma glucosec Not applicable ‡200 mg/dL
Hemoglobin A1c 5.7–6.4% ‡6.5%
Adapted from the American Diabetes Association
Recommendations.50
aFasting for at least 8 hours with no calorie intake.
bOGTT using a load 1.75 g/kg of body weight of glucose with a
maximum of 75 g.
cIn patients with hyperglycemic crises or classic symptoms of
hyperglycemia (e.g., polyuria, polydipsia).
dIn the absence of unequivocal hyperglycemia, diagnosis is confirmed
if two different tests are above threshold or a single test is above
threshold twice.
OGTT, oral glucose tolerance test; A1c, glycosylated hemoglobin.
Table 2. Comparison of Tests To Screen
for Prediabetes
Fasting plasma glucose Hemoglobin A1c
 Higher sensitivity compared
to A1c in adult populations
(in adults up to one third
more diagnosed)50
 Unaffected by conditions
associated with high red blood
cell turnover (e.g., anemia,
blood transfusion, pregnancy)
 Less expensive and more
convenient compared to OGTT
 Low reproducibility
 Fasting is not required.
 Low intraindividual variability
 Less day-to-day variability with
illness or stress
 Reflects glycemic levels for the
past 3 months
 Good predictor of diabetes-
related complications
in adults50
OGTT, oral glucose tolerance test; A1c, glycosylated hemoglobin.
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two used a cutoff based on onset of puberty and BMI
> 85th percentile. Additional screening factors used in-
cluded family history of T2DM (n = 3) and ethnicity
(n = 1). Three clinics choosing not to screen for insulin
levels reported the following reasons: Data did not change
management, desire to conserve financial resources, and
advice from endocrinologists at the institution who re-
commended screening for abnormal blood glucose mea-
sures only.
Consensus statement of Focus on a Fitter Future on
clinical screening using laboratory tests. FPG, A1c, and
OGTT can be used to screen for prediabetes in children
presenting to tertiary weight management programs at
the earlier age of 10 or onset of puberty (Evidence B; see
Table 1 for details). The authors recognize the option for
clinicians to select from one or more of the available
tests.
Testing can be considered in younger children with
severe obesity or children prescribed SGAPs.
The authors do not support laboratory screening for
fasting insulin in obese patients because current evidence
does not indicate changes to treatment based on results,
and insulin levels may be low as patients lose insulin
secretory ability. Thus, low insulin levels may represent
worsening of beta-cell status, rather than improvement in
IR (Evidence D).
Further study is needed of the predictive value of
laboratory markers of blood glucose and IR over time
for progression to T2DM, especially in severely obese
children and other groups expected to be at highest
risk.
Type 2 Diabetes Prevention
Halting the progression toward T2DM, both from nor-
mal glucose regulation to prediabetes and from prediabetes
to diabetes, is one of the key goals of obesity management.
Several studies have shown that lifestyle change consisting
of physical activity, lower daily energy intake, and modest
weight reduction can reduce T2DM incidence in adults at
high risk for diabetes.31,62–64 The progression to T2DM
typically occurs in individuals who are overweight or ob-
ese and sedentary. Resistance to the action of insulin in
liver and skeletal muscle can lead to hyperinsulinemia,
often marked by the presence of acanthosis nigricans, es-
pecially in more darkly pigmented individuals. Pancreatic
beta cells may eventually fatigue as IR worsens, and
waning insulin secretion leads to moderate glucose ex-
cursions in prediabetes. More-advanced beta-cell failure,
in the presence of persistent IR, results in overt T2DM as
glucose toxicity further impairs insulin secretion and leads
blood glucose to rise uncontrollably.65 Intensifying inter-
ventions early in the disease course, with the goals of
glucose normalization and preservation of pancreatic beta-
cell function, seems to offer the best chance for preventing
the development of diabetes or slowing the progression to
diabetes.31 While new cases of T2DM occurred in the in-
tervention arms of the DPP over time, the incidence of
T2DM remained below that of the control group. Thus, the
ADA’s Professional Practice Committee recommends that
adults with prediabetes be referred to a program targeting
weight loss of 7% and increasing moderate physical ac-
tivity to > 150 minutes per week based on data from the
DPP.50 Studies in adolescents have also demonstrated an
increase in insulin sensitivity with diet and exercise-induced
weight loss66,67 and resolution of prediabetes in multi-
component lifestyle programs.68–70
Role of medication in diabetes prevention. IR precedes
development of T2DM, which occurs when pancreatic
beta cells fail to compensate for IR. Several large RCTs of
pharmacological interventions to decrease the incidence
of new-onset T2DM have been conducted in adults with
mixed results.71,72 Metformin, a biguanide, decreases he-
patic glucose production and also increases insulin sensi-
tivity in peripheral tissues.73 In the DPP trial, metformin, at
a dose of 850mg twice-daily, showed a 31% reduction in
risk, compared to placebo, over 2.8 years (compared to a
58% reduction in the lifestyle group).31,50 A meta-analysis
from five randomized clinical trials of adults on metformin
found a 40% decline in progression to type 2 diabetes
among those at risk.72
In obese adolescents, a meta-analysis including three
small, short-term randomized trials of metformin with IR
found a reduction in BMI and fasting insulin with treat-
ment.74 Three other small randomized trials in normogly-
cemic obese children with elevated fasting insulin showed
reduction in fasting glucose and insulin.75–77 However,
none of these studies lasted longer than 6 months.
Clinical practice findings for use of metformin in predia-
betes. Among children’s hospital obesity programs, 14
of 28 respondents (50%) indicated that they use metformin
to treat prediabetes, and the doses prescribed ranged
from 500 to 2000mg per day. Seven of these 14 clinics
treating prediabetes with metformin reported systemati-
cally tracking patient results, including BMI and labora-
tory values. Eight respondents reported using laboratory
triggers for referral to endocrinology: elevated fasting
glucose > 100mg/dL (n = 4), abnormal OGTT (n = 3), and
A1c > 5.7% (n = 1). Reasons for stopping metformin in-
cluded improvement in blood glucose (n = 5), decrease in
BMI of 2 kg/m2 (n = 1), and improvement in insulin
(n = 1). Three respondents indicated that an endocrinolo-
gist was routinely consulted regarding the decision to stop
metformin.
Clinical practice findings for use of metformin in insulin
resistance. In addition to the use of metformin for predia-
betes, 11 programs reported prescribing metformin for
elevated fasting insulin or HOMA-IR in the absence of
abnormal blood sugar or polycystic ovary syndrome.
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Consensus statement of Focus on a Fitter Future on
type 2 diabetes mellitus prevention using pharmaceuti-
cals. The Committee takes no position on the use of
pharmacological agents to prevent T2DM in children
with prediabetes or elevated fasting insulin, given the
limited studies in children and evidence that many
children with prediabetes may revert to normoglycemia
without pharmacological treatment (Evidence C). The
authors call for further long-term study of the safety and
efficacy of medication treatment of prediabetes to pre-
vent T2DM in children, recognizing that the scale of
such a study must be large and the duration long, even
when populations at highest risk of T2DM are targeted.
Role of nutrition in diabetes prevention. Support for
healthy nutrition is essential for management and preven-
tion of diabetes. Medical nutrition therapy with a registered
dietitian provides specialized support in treating youth with
prediabetes and T2DM. Of note, studies of dietary inter-
ventions reviewed below have employed registered dieti-
tians to design and deliver the nutrition interventions.
Weight loss of 5–7% is the standard recommendation for
diabetes prevention in adults based on the DPP, which used
a low-fat diet to decrease calorie intake.78 Research studies
to inform similar recommendations in youth are needed,
especially during critical periods of increased IR, such as
puberty.79 Studies suggest that lifestyle intervention in
children also leads to metabolic improvement.80
Although there is no prescribed diet for diabetes pre-
vention in youth, research on low glycemic diets among
adults81–83 and youth84–88 demonstrate improvement in
insulin secretion and body composition without evidence
of harm. A low glycemic index (GI) diet generally refers to
a balanced diet with carbohydrate content primarily from
low to medium glycemic load foods (those that produce
less-rapid rise in blood glucose and have lower overall
carbohydrate content).89 The most common high GI foods
include processed grains (white bread and white rice) and
added sugars of all types. In two studies comparing low
and high GI diets in 38 youth with obesity and T2DM or
prediabetes, the low GI diet had significantly greater re-
ductions in IR.86,87 Additional research found a low GI diet
decreased adipose tissue more than low-kilocalorie and
low-fat diets67,88 and increased high-density lipoprotein
cholesterol and satiety.88 An RCT comparing low versus
high glycemic load hypocaloric diets for 6 months found
greater reductions in waist circumference, BMI z-score,
and HOMA-IR with the low GI diet.90
In children who are severely obese, few studies examined
the safety and effectiveness of rapid weight loss diets. A
study of 46 adolescents randomized to a low-calorie, low-fat
diet or a very-low-carbohydrate (20 g/day) diet demonstrated
safety and efficacy of the very-low-carbohydrate diet.91
Another study comparing 58 children randomized to either a
very-low-carbohydrate ketogenic diet or a hypocaloric diet
for 6 months found greater improvements with the ketogenic
diet in weight, fat mass, waist circumference, fasting insulin,
and HOMA-IR.92 Larger and longer-term studies of very-
low-carbohydrate diets for severely obese children with
prediabetes are needed.
Role of exercise in diabetes prevention. Exercise, com-
bined with healthful dietary changes using a behavioral
approach, is a key therapeutic recommendation for obesity
reduction and T2DM prevention.32 In studies of adults,
exercise increases insulin sensitivity within 1 week of an
intervention, lasting for 3–4 days after exercising.93 In
obese children, exercise alone has been shown to improve
IR even without changes in body weight or body compo-
sition. A variety of exercise interventions have been tested,
including 1-hour circuit training sessions three times per
week, sports activities for 20–45 minutes three times per
week, and progressive resistance training.94–96 Individual
differences in physiological changes with exercise depend
on baseline fitness, genetic effects, and lifestyle.97
Consensus statements of Focus on a Fitter Future on
T2DM prevention using diet and physical activity. The
Committee supports dietary intervention to manage
weight, specifically a low GI diet implemented by reg-
istered dietitians, to influence metabolic risk factors for
T2DM in prediabetic children (Level of Evidence B).
More-severe carbohydrate restriction may be consid-
ered for severely obese children with prediabetes under
medical supervision. More study is needed on long-term
effects of diet on T2DM prevention in severely obese
children and adolescents. For physical activity, though
there are no pediatric recommendations for exercise
specifically to prevent diabetes, the Committee strongly
supports an increased level of moderate-to-vigorous
physical activity for children with prediabetes (Evi-
dence B). The AAP recommends 60 minutes of mod-
erate-to-vigorous activity daily for all youth.32
Role of behavioral health professionals in diabetes pre-
vention. Standard practice for treating childhood obesity
in multidisciplinary referral settings includes behavioral
health services32 delivered by a doctoral-level pediatric
psychologist, if possible. There is emerging literature un-
derscoring the benefits of including a behavioral health
specialist in treating T2DM.98,99 Earlier involvement of
behavioral health professionals for those with prediabetes
may help prevent disease progression. As in treating obe-
sity,32,100 targeting behavioral treatment to the family unit
of youth with prediabetes or T2DM may be especially
important, given high rates of T2DM and problematic
behaviors among family members.
In addition to facilitating family-based lifestyle behav-
ior change, psychologists can address comorbid psychopa-
thology that contributes to disease progression or hinders
treatment. Emotional and behavioral difficulties represent
barriers to adherence with pediatric medical regimens in
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general.101 Almost 1 in 5 youth with newly diagnosed T2DM
may have pre-existing psychiatric diagnoses.102 Researchers
have found that the progression of IR during childhood and
adolescence is predicted by depressive symptomatology at
baseline, independent of BMI.103 Psychologists also can be
instrumental in addressing other adherence barriers, such as
family conflict and poor time management.101
Psychologists can aid a multidisciplinary team in providing
culturally effective pediatric healthcare.104 Children and ad-
olescents from low socioeconomic backgrounds, ethnic mi-
nority groups, and single-parent families tend to have more
problems with adherence to complex chronic disease regi-
mens.101 In general, racial and ethnic minorities utilize mental
health services at lower rates than non-Latino whites.105,106
Therefore, pediatric psychologists working with children and
adolescents with prediabetes should be sensitive to cultural
issues and tailor their interventions for each family.107
Consensus statement of Focus on a Fitter Future on the
role of behavioral health professionals in T2DM preven-
tion. The Committee supports including pediatric psy-
chologists, or other trained behavioral health specialists,
in care teams to manage prediabetes using behavioral
treatment approaches (Evidence C).
Referral to Endocrinology/Diabetes Specialists
The ADA recommendations state that children meeting
criteria for T2DM are to be referred to endocrine special-
ists to confirm diagnosis and discuss decisions about
medication and how to manage comorbidities.50 An en-
docrinologist should be consulted to distinguish between
type 1 and 2 diabetes.2 The AAP recommends that weight
management specialists co-manage T2DM with a pediatric
endocrinologist.108 A primary care professional (pediatri-
cian, family practitioner, or internist) who has expertise in
diabetes management may serve as a consultant in the
absence of an available pediatric endocrinologist.50
Clinical practice findings for co-management with an en-
docrinologist. Whereas some pediatric obesity clinics are
directed by an endocrinologist, others have more-limited
access to endocrinologists. Almost all of the children’s
hospital obesity clinics in our survey (n= 23 of 25; 92%) do
not include endocrinologists on the weight management
team; all of these refer patients with T2DM to endocri-
nology, primarily for medication management. The ma-
jority of respondents (n= 16 of 22; 72%) indicated that they
do not refer patients with prediabetes to endocrinologists.
Consensus statement of Focus on a Fitter Future on
co-management of T2DM with an endocrinologist. Con-
sistent with AAP recommendations108 the Committee
supports that weight management specialists co-manage
T2DM with a pediatric endocrinologist (Evidence D).
Conclusion
Given the increased prevalence of prediabetes and T2DM
among children, guidance regarding screening and man-
agement of prediabetes is needed to ensure best clinical
outcomes and reduce healthcare costs. However, data to
guide T2DM prevention in children are limited. This article
summarizes the current literature on screening and diagnosis
of prediabetes and the prevention of T2DM among over-
weight youth. Variability in practices in assessment and
treatment of IR and prediabetes may be attributed to the lack
of high-quality evidence and limited availability of pediatric
endocrinology expertise. Based on the best available evi-
dence, our experience in treating obese children, and con-
sideration of possible harms and benefits, the authors offer
statements of support reflecting consensus of the FFF
Medical Management Committee with consideration of the
level of evidence, uniformity of current practice, potential
costs, and benefits for practices that were reviewed (Table 4).
Further research is needed to guide which therapies
might best prevent progression of prediabetes to T2DM
and which children should be targeted. In order to answer
important clinical and public health questions, large-scale,
multi-center studies of interventions to reduce the risk of
T2DM are needed. A multi-center research network of
childhood obesity treatment programs, working collabo-
ratively with multidisciplinary teams including pediatric
endocrinologists, could provide the platform required to
answer many of these questions.
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